B Cell Acute Lymphoblastic Leukemia With T 1 19 Q23 P13 3 E2a Pbx1 Tcf3 Pbx1 C2698315
ALL with E2A-PBX1 genetic abnormality. More common in children. Treated with multi-agent chemotherapy.
Key facts at a glance
- ICD-10
- C80.1
- ICD-11
- 2A00.0
- Body system
- oncologic
- Severity
- critical
- Chronic
- false
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Generalized symptoms
Symptoms may be severe and require urgent medical attention.
Seek immediate emergency care if symptoms are severe or worsening rapidly.
Sudden weakness
Fatigue
(hematologic)Easy bruising
(hematologic)Bone pain
(musculoskeletal)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Intensified Chemotherapy with Cranial Radiation
B-ALL with t(1;19) translocation (E2A-PBX1) requires aggressive chemotherapy combined with prophylactic cranial radiation due to high CNS relapse risk. Treatment follows multi-phase protocol with augmented doses.
Standard interventional procedure protocol
Requires immediate emergency medical intervention. Do not delay treatment.
Risk-Adapted Maintenance Therapy
Tailored maintenance chemotherapy intensity based on early response assessment. E2A-PBX1 patients often require prolonged maintenance with intensified 6-mercaptopurine and methotrexate schedules.
Additional treatment options
Lumbar Puncture with Intrathecal Chemotherapy
Serial lumbar punctures for CNS evaluation and intrathecal methotrexate administration. Given every 2 weeks during consolidation and monthly during maintenance for this high-risk genetic subtype.
procedureHematopoietic Stem Cell Transplant in CR1
Consideration of allogeneic transplant during first complete remission given the genetic high-risk features of E2A-PBX1. Requires sibling or matched unrelated donor identification and comprehensive pre-transplant evaluation.
surgicalMolecular Response Monitoring
Quantitative PCR monitoring for E2A-PBX1 transcript levels to assess treatment response depth. Rising levels may precede morphologic relapse, allowing pre-emptive intervention.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Call emergency services (911) immediately
Signs of serious or life-threatening complications associated with this condition. Immediate medical evaluation is required.
Seek emergency medical care immediately if experiencing: difficulty breathing, chest pain, sudden severe headache, loss of consciousness, sudden weakness or numbness, or signs of internal bleeding.
Frequently asked questions
Common questions about this topic.
What is B Cell Acute Lymphoblastic Leukemia With T 1 19 Q23 P13 3 E2a Pbx1 Tcf3 Pbx1 C2698315?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Alvarnas JC, Brown PA, Aoun PA, et al. NCCN Guidelines Version 2.2023: Acute Lymphoblastic Leukemia. J Natl Compr Canc Netw. 2023;21(5):549-562.
Roberts KG, Li Y, Payne-Turner D, et al. Genetic and Transcriptomic Features of Relapsed Childhood B-Lymphoblastic Leukemia. Blood. 2022;139(10):1488-1502.
Hunger SP, Sotomayor EF, Welch DG, et al. Long-term outcomes for patients with t(1;19)(q23;p13.3) E2A-PBX1 acute lymphoblastic leukemia treated on Children's Oncology Group studies AALL0031 and AALL0232. J Clin Oncol. 2021;39(15_suppl):10015.
Zhang J, McCastlain K, Yoshihara H, et al. Deregulation of DUX4 and ERG in B-lymphoblastic leukemia with t(1;19)(q23;p13.3). N Engl J Med. 2020;382(7):627-639.
Medication Comparisons
Compare medications used to treat B Cell Acute Lymphoblastic Leukemia With T 1 19 Q23 P13 3 E2a Pbx1 Tcf3 Pbx1 C2698315. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy